Machine learning-based differentiation between multiple sclerosis and glioma WHO II°-IV° using O-(2-[18F] fluoroethyl)-L-tyrosine positron emission tomography
Authors:
- 27 January 2021
- journal article
- research article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 152 (2) , 325-332
Abstract
Introduction This study aimed to test the diagnostic significance of FET-PET imaging combined with machine learning for the differentiation between multiple sclerosis (MS) and glioma II°-IV°. Methods Our database was screened for patients in whom FET-PET imaging was performed for the diagnostic workup of newly diagnosed lesions evident on MRI and suggestive of glioma. Among those, we identified patients with histologically confirmed glioma II°-IV°, and those who later turned out to have MS. For each group, tumor-to-brain ratio (TBR) derived features of FET were determined. A support vector machine (SVM) based machine learning algorithm was constructed to enhance classification ability, and Receiver Operating Characteristic (ROC) analysis with area under the curve (AUC) metric served to ascertain model performance. Results A total of 41 patients met selection criteria, including seven patients with MS and 34 patients with glioma. TBR values were significantly higher in the glioma group (TBRmax glioma vs. MS: p = 0.002; TBRmean glioma vs. MS: p = 0.014). In a subgroup analysis, TBR values significantly differentiated between MS and glioblastoma (TBRmax glioblastoma vs. MS: p = 0.0003, TBRmean glioblastoma vs. MS: p = 0.0003) and between MS and oligodendroglioma (ODG) (TBRmax ODG vs. MS: p = 0.003; TBRmean ODG vs. MS: p = 0.01). The ability to differentiate between MS and glioma II°-IV° increased from 0.79 using standard TBR analysis to 0.94 using a SVM based machine learning algorithm. Conclusions FET-PET imaging may help differentiate MS from glioma II°-IV° and SVM based machine learning approaches can enhance classification performance.Keywords
This publication has 34 references indexed in Scilit:
- Diagnostic Performance of 18F-FET PET in Newly Diagnosed Cerebral Lesions Suggestive of GliomaJournal of Nuclear Medicine, 2012
- First Clinical Experience with Integrated Whole-Body PET/MR: Comparison to PET/CT in Patients with Oncologic DiagnosesJournal of Nuclear Medicine, 2012
- The Clinical Value of PET with Amino Acid Tracers for Gliomas WHO Grade IIInternational Journal of Molecular Imaging, 2011
- Hybrid PET/MRI of Intracranial Masses: Initial Experiences and Comparison to PET/CTJournal of Nuclear Medicine, 2010
- Is there a place for FET PET in the initial evaluation of brain lesions with unknown significance?European Journal of Nuclear Medicine and Molecular Imaging, 2010
- Distinguishing Tumefactive Demyelinating Lesions from Glioma or Central Nervous System Lymphoma: Added Value of Unenhanced CT Compared with Conventional Contrast-enhanced MR ImagingRadiology, 2009
- An image-analysis system based on support vector machines for automatic grade diagnosis of brain-tumour astrocytomas in clinical routineMedical Informatics and the Internet in Medicine, 2005
- Astrocytoma-like multiple sclerosisClinical Neurology and Neurosurgery, 2005
- Whole-body distribution and dosimetry of O-(2-[18F]fluoroethyl)-l-tyrosineEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- O-(2-[18F]Fluoroethyl)-L-tyrosine (FET): a tracer for differentiation of tumour from inflammation in murine lymph nodesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2002